7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $15M | -$276M | 0.0% | -1971.6% | -48.8% | -44.5% | -$236M | — | $84M |
| 2024 | $10M | -$338M | 0.0% | -3722.1% | -43.4% | -38.8% | -$251M | — | $124M |
| 2023 | $26M | -$342M | 0.0% | -1460.1% | -45.5% | -40.5% | -$304M | — | $144M |
| 2022 | $1M | -$291M | 0.0% | -21670.9% | -30.6% | -26.4% | -$239M | — | $152M |
| 2021 | $3M | -$364M | 0.0% | -12040.2% | -40.5% | -36.1% | -$78M | — | $280M |
| 2020 | $83M | -$52M | 0.0% | -67.5% | -6.9% | -6.6% | -$104M | — | $448M |
| 2019 | — | -$75M | — | — | 41.7% | -19.2% | -$74M | — | $42M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $350000 | -$84M | 0.0% | -25949.7% | -9.4% | -8.7% | — | — | $121M |
| Mar '26 | $3M | -$73M | 0.0% | -2619.7% | -11.4% | -10.5% | — | — | $205M |
| Dec '25 | $7M | -$55M | 0.0% | -866.1% | -9.7% | -8.8% | -$45M | — | $84M |
| Sep '25 | $0 | -$74M | — | — | -12.2% | -11.1% | -$62M | — | $92M |
| Jun '25 | $677000 | -$70M | 0.0% | -11351.1% | -10.6% | -9.7% | -$55M | — | $114M |
| Mar '25 | $8M | -$77M | 0.0% | -1105.2% | -10.7% | -9.6% | -$74M | — | $94M |
| Dec '24 | $0 | -$76M | — | — | -9.8% | -8.7% | -$58M | — | $124M |
| Sep '24 | $0 | -$88M | — | — | -10.5% | -9.5% | -$75M | — | $152M |
| Jun '24 | $0 | -$92M | — | — | -13.5% | -11.9% | -$66M | — | $134M |
| Mar '24 | $10M | -$81M | 0.0% | -903.0% | -10.9% | -9.7% | -$52M | — | $153M |
| Dec '23 | -$1000 | -$83M | 0.0% | 9219600.0% | -11.1% | -9.9% | -$89M | — | $144M |
| Sep '23 | $25M | -$66M | 0.0% | -291.9% | -8.4% | -7.2% | -$76M | — | $151M |
| Jun '23 | $119000 | -$99M | 0.0% | -89117.6% | -12.2% | -10.2% | -$70M | — | $146M |
| Mar '23 | $226000 | -$94M | 0.0% | -44768.6% | -10.7% | -9.1% | -$69M | — | $161M |
| Dec '22 | $253000 | -$68M | 0.0% | -28794.9% | -7.1% | -6.1% | -$59M | — | $152M |
| Sep '22 | $344000 | -$84M | 0.0% | -24968.6% | -8.4% | -7.2% | -$68M | — | $355M |
| Jun '22 | $365000 | -$77M | 0.0% | -21318.1% | -9.8% | -8.6% | -$59M | — | $108M |
| Mar '22 | $419000 | -$62M | 0.0% | -14969.2% | -7.4% | -6.5% | -$52M | — | $119M |
| Dec '21 | $567000 | -$67M | 0.0% | -11944.1% | -7.5% | -6.7% | -$41M | — | $280M |
| Sep '21 | $666000 | -$61M | 0.0% | -9157.7% | -10.7% | -9.1% | -$55M | — | $229M |
How the market has priced RLAY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Relay Therapeutics, Inc.'s revenue has declined 28.6% per year. These are computed facts, not advice.
As of FY2025, Relay Therapeutics, Inc. reported — of total debt against $84M of cash.
In FY2025, gross margin was —, operating margin -1971.6%, and net margin -1800.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.